Evidence map›Paper›PMID 32252475›Full record

ArticleCells2020

Human Embryonic Stem Cell-Derived Wilson's Disease Model for Screening Drug Efficacy.

Dongkyu Kim, Su-Bin Kim, Jung Lim Ryu, Heesu Hong, Jin-Hyuk Chang, Tack-Jin Yoo, Xiong Jin, Han-Jin Park, Choongseong Han, Beom Hee Lee and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Dongkyu KimDepartment of Stem Cell Research, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.
Su-Bin KimDepartment of Stem Cell Research, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.
Jung Lim RyuDepartment of Stem Cell Research, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.
Heesu HongDepartment of Stem Cell Research, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.
Jin-Hyuk ChangDepartment of Stem Cell Research, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.
Tack-Jin YooDepartment of New Drug Development, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.
Xiong JinDepartment of New Drug Development, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.
Han-Jin ParkPredictive Model Research Center, Korea Institute of Toxicology, Daejeon 34114, Korea.
Choongseong HanDepartment of Stem Cell Research, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.ORCID 0000-0003-4688-0915
Beom Hee LeeDepartment of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul 05505, Korea.
Jin-Ho ChoiDepartment of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul 05505, Korea.
Han-Wook YooDepartment of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul 05505, Korea.
Jong-Hoon KimLaboratory of Stem Cells and Tissue Regeneration, Department of Biotechnology, College of Life Sciences and Biotechnology, Science Campus, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea.
Dong-Hun WooDepartment of Stem Cell Research, NEXEL Co., Ltd., 8th floor, 55, Magokdong-ro, Gangseo-gu, Seoul 07802, Korea.ORCID 0000-0001-7470-018X
Ulsan College · KRKorea Institute of Toxicology · KRKorea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human pluripotent stem cells (hPSCs) including human embryonic stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs) have been extensively studied as an alternative cellular model for recapitulating phenotypic and pathophysiologic characters of human diseases. Particularly, hiPSCs generated from the genetic disease somatic cells could provide a good cellular model to screen potential drugs for treating human genetic disorders. However, the patient-derived cellular model has a limitation when the patient samples bearing genetic mutations are difficult to obtain due to their rarity. Thus, in this study, we explored the potential use of hPSC-derived Wilson's disease model generated without a patient sample to provide an alternative approach for modeling human genetic disease by applying gene editing technology. Wilson's disease hPSCs were generated by introducing a R778L mutation in the

Indexed as

Cell DifferentiationCopperDrug Evaluation, PreclinicalHepatolenticular DegenerationHuman Embryonic Stem CellsHumansCoppercopper toxicityCRISPR/Cas9drug screening systemhepatocyte differentiationhuman embryonic stem cellWilson’s disease

Identifiers

PMID32252475
PMCPMC7226780
OpenAlexW3015144006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.